IL13Ra2-DBTE

IL13Ra2-DBTE is a DNA-encoded bispecific T-cell engager (DBTE) designed for the treatment of glioblastoma multiforme (GBM). Developed by researchers at The Wistar Institute and the University of Pennsylvania, the therapy utilizes a DNA plasmid platform to facilitate the in vivo production of bispecific antibodies following intramuscular administration. The construct consists of single-chain variable fragments (scFvs) targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Ra2) and the CD3 epsilon subunit of the T-cell receptor complex. Upon expression, the bispecific molecule bridges T cells and IL13Ra2-expressing tumor cells, inducing T-cell activation and targeted cytotoxicity. In preclinical studies, IL13Ra2-DBTE has been evaluated both as a monotherapy and as a component of multi-specific strategies to address the antigenic heterogeneity characteristic of GBM.

Other names

DNA-encoded Tumor Attacking Bridge targeting IL13Rα2